AACAP practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry .
2007; 46: 273–274
AACAP practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry .
2007. FOCUS. Summer 2008; 6(3): 380–381, 387–389
AACAP practice parameter for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. J Am Acad Child Adolesc Psychiatry .
1999; 38: 1609
AACAP practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry .
2007. FOCUS. Summer 2008; 6(3): 401–426
AACAP Practice parameter of the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry . FOCUS. Fall
2004; 2(4): 644–645
AACAP Practice Parameter for the Assessment and Treatment of Children and Adolescents with Oppositional Defiant Disorder. J Am Acad Child Adolesc Psychiatry 46:1126–41
Abrams
RC;
Lachs
M;
McAvay
G;
Keohane
DJ;
Bruce
ML.
Predictors of self-neglect in community-dwelling elders. Am J Psychiatry .
2002
Oct; 159(10): 1724–30
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Text Revision (DSM-IV-TR).
Washington DC,
American Psychiatric Association,
2000. pp 75, 121–124, 298–317, 323–329, 350, 355–356, 372–373, 419–422, 425–426, 430–441, 449–453, 455, 463–468, 472–476, 800–802
Bakker
A;
van Balkom
AJ;
Stein
DJ.
Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol
2005; 8:473–482
Bloch
MH;
Peterson
BS;
Scahill
L;
Otka
J;
Katsovich
L;
Zhang
H;
Leckman
JF.
Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med .
2006
Jan; 160(1): 65–9
Boylan
K;
Romero
S;
Birmaher
B.
Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacol
2007; 191: 27–38
Buckley
PF;
Foster
A;
Miller
B.
Schizophrenia host vulnerability and risk of metabolic disturbance during treatment with antipsychotics. FOCUS: Schizophrenia . Spring
2008; 6(2) 172–179
Bulik
CM;
Berkman
ND;
Brownley
KA;
Sedway
JA;
Lohr
KN.
Anorexia nervosa treatment: a systematic review of randomized controlled trials. International Journal of Eating Disorders . 40(4):310–20,
2007
May40:310–20
Bystritsky
A.
Diagnosis and treatment of anxiety. FOCUS summer
2004; 3: 333–342
Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation .
2008
May 6; 117(18) pp 2407–23Epub 2008 Apr 21
Clayton
AH;
Croft
HA;
Horrigan
JP;
Wightman
DS;
Krishen
A;
Richard
NE;
Modell
JH.
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry .
2006; 67:736–746
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. (Reviews/Commentaries/Position Statements). Diabetes Care .
2004; 27: 596–601
Correll
CU;
Carlson
HE:
Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child & Adolescent Psychiatry .
2006; 45:771–91
Crossley
NA;
Bauer
M.
Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry .
2007
Jun; 68(6):935–40
Davidson
JRT.
Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry .
2006; 67(suppl 12): 20–26
Delong
H;
Pollack
M.
Update on the assessment, diagnosis, and treatment of individuals with social anxiety disorder. FOCUS: Panic and Social Phobia . Fall
2008; (6)4
Dickerson
FB;
Lehman
AF:
Evidence-based psychotherapy for schizophrenia. J of Nervous & Mental Disease .
2006; 194:3–9
Dulcan
MK;
Wiener
JM.
Essentials of Child and Adolescent Psychiatry,
Arlington VA,
American Psychiatric Publishing, Inc.,
2006. pp.129–130, 238–240, 268–270, 273–274, 341–342, 374, 527–528, 558
Dyer
CB;
Pavlik
VN;
Murphy
KP;
Hyman
DJ.
The high prevalence of depression and dementia in elder abuse or neglect. J Am Geriatr Soc .
2000
Feb; 48(2): 205–8
Emslie
GJ;
Kennard
BD;
Mayes
TL;
Nightingale-Teresi
J;
Carmody
T;
Hughes
CW;
Rush
AJ;
Tao
R;
Rintelmann
JW.
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry
2008; 165:459–467. FOCUS: Child and Adolescent Psychiatry. Summer 2008; 6(3): 356
Foa
EB.
Social anxiety disorder treatments: psychosocial therapies. J Clin Psychiatry
2006; 67(suppl 12):27–30
Goddard
AW;
Brouette
T;
Almai
A;
Jetty
P;
Woods
SW;
Charney
D.
Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry .
2001
Jul;58(7):681–6.
Golden
RN;
Bradley
N;
Gaynes
R;
Ekstrom
D;
Hamer
RM;
Jacobsen
FM;
Suppes
T;
Wisner
KL;
Nemeroff
CB.
The efficacy of light therapy in the treatment of mood disorder: A review and meta-analysis of the evidence. Am J Psychiatry .
Apr
2005; 162(4): 656–662
Haddad
PM;
Dursun
SM.
Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol .
2008
Jan: 23Suppl 1: 15–26
Hales
RE;
Yudofsky
SC;
Gabbard
GO (eds): The American Psychiatric Publishing Textbook of Psychiatry , 5th ed.
Washington, DC,
American Psychiatric Publishing,
2008. pp 208, 424–426, 472, 522, 534–35, 542–545, 577, 836, 882–892, 895, 974, 1097–1098, 1104
Handen
B;
Gilchrist
R.
Practitioner review: psychopharmacology in children and adolescents with mental retardation. Journal of Child Psychology & Psychiatry and Allied Disciplines .
2006; 47: 871–82
Jacobson
SA;
Pies
RW;
Katz
IR. Clinical Manual of Geriatric Psychopharmacology .
Arlington, VA,
American Psychiatric Publishing, Inc.,
2007. pp 191–192
Kane
JM;
Davis
JM;
Schooler
N;
Marder
S;
Casey
D;
Brauzer
B;
Mintz
J;
Conley
R.
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry .
2002; 159:554–60
Kay
J;
Tasman
A. Essentials of Psychiatry .
John Wiley and Sons,
Hoboken, NJ.
2006, pp 399–401, 952–954.
Lasser
RA;
Bossie
CA;
Zhu
Y;
Locklear
JC;
Kane
JM.
Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry .
2007
Apr-Jun; 19(2):65–71.
Lauriello
J;
Bustillo
JR;
Shingler
KC:
The first interview of a patient with psychosis: symptoms, safety, and stabilization. FOCUS: Schizophrenia . Winter
2004; 2(1): 7–12
Leckman
JF;
Zhang
H;
Vitale
A;
Lahnin
F;
Lynch
K;
Bondi
C;
Kim
Y;
Peterson
BS.
Course of tic severity in tourette syndrome: the first two decades. Pediatrics .
1998
July; 102(1): 14–19
Levenson
JL (editor): Essentials of Psychosomatic Medicine .
Arlington, VA,
American Psychiatric Publishing, Inc.,
2007. pp 213–14
Lieberman
JA;
Stroup
TS;
McEvoy
JP;
Swartz
MS;
Rosenheck
RA;
Perkins
DO;
Keefe
RS;
Davis
SM;
Davis
CE;
Lebowitz
BD;
Severe
J;
Hsiao
JK.
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med .
2005; 353(12): 1209–23
March
JS;
Silva
S;
Petrycki
S;
Curry
J;
Wells
K;
Fairbank
J;
Burns
B;
Domino
M;
McNulty
S;
Vitiello
B;
Severe
J,
Treatment for Adolescents with Depression Study (TADS) team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association .
2004
Aug 18; 292(7): 807–820
Marder
SR.
Neurocognition as a treatment target in schizophrenia. FOCUS: Schizophrenia . Spring
2008; 6(2): 180–183
Martin
A;
Volkmar
FR (eds) Lewis' Comprehensive Textbook of Child and Adolescent Psychiatry 4th ed.
Philadelphia,
Lippincott Williams & Wilkins;
2007, pp 143, 692–701, 859–860
McClellan
J;
Kowatch
R;
Findling
RL;
Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry .
2007; 46(1): 107–25
Mitte
K.
A meta-analysis of the efficacy of psychoand pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord
2005; 88:22–45
Miyamoto
S;
Duncan
GE;
Marx
CE;
Lieberman
JA.
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic medications. Mol Psychiatry .
2005,
Jan; 10(1):79–104
Modell
JG;
Katholi
CR;
Modell
JD;
DePalma
RL.
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther .
1997; 61: 476–487
Moore
THM;
Zammit
S;
Lingford-Hughes
A;
Barnes
TRE;
Jones
PB;
Burke
M;
Lewis
G.
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet
2007; 370:319–28
Muller
JE;
Koen
L;
Seedat
S;
Stein
DJ.
Social anxiety disorder: current treatment recommendations. CNS Drugs
2005; 19: 377–391
Murray
CJL;
Lopez
AD:
The Global Burden Of Disease: A Comprehensive Assessment Of Mortality And Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020.
Cambridge, MA,
Harvard University Press,
1996(Table 5.4)
Naqvi
S.
Review of child and adolescent psychiatry. FOCUS: Child and Adolescent Psychiatry . Fall
2004; 2(4): 536–7
Nasrallah
HA.
The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry .
2007; 68Suppl 1:5–11
Nierenberg
AA;
Katz
J;
Fava
M.
A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am
2007
Mar; 30(1):13–29
NIMH Genetics Workgroup.
Report of the NIMH Genetic's Workgroup: Summary of Research. Biological Psychiatry .
1999; 45:573–602.
Payne
JL.
Antidepressant use in the postpartum period: practical considerations. Am J Psychiatry .
2007
Sep; 164(9): 1329–32
Pocket Handbook of Clinical Psychiatry , 4th ed,
Sadock BA and Sadock VA, Lippinicott,
Williams and Wilkins,
2005. p 161
Pollack
MH;
Allgulander
C;
Bandelow
B;
Cassano
GB;
Greist
JH;
Hollander
E;
Nutt
DJ;
Okasha
A;
Swinson
RP.
WCA recommendations for the long-term treatment of panic disorder. CNS Spectrums
2003; 8(suppl 1):17–30
Pollack
MH;
Simon
NM;
Worthington
JJ;
Doyle
AL;
Peters
P;
Toshkov
F;
Otto
MW.
Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol .
2003
Sep;17(3):276–82.
Practice Guideline for the Treatment of Patients with Eating Disorders, 3rd ed. (
2005), in American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2006 .
Arlington, VA,
American Psychiatric Association. p1110
http://www.psychiatryonline.com/pracGuide/pracGuideHome.aspx
Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd ed. (
2000). In American Psychiatric Association Practice Guideline for the Treatment of Psychiatric Disorders, Compendium 2006 .
Arlington, VA,
American Psychiatric Association, 2006. pp 777–778, 784, 785, 789, 791, 812, 815–817, 812, p 795, 806–807
http://www.psychiatryonline.com/pracGuide/pracGuideHome.aspx
Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed (
2004). In American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2006 .
Arlington, VA,
American Psychiatric Association, 2006. pp 576, 636, pp 577–78, 607–608, 586–7, 272–273, 659–60
http://www.psychiatryonline.com/pracGuide/pracGuideHome.aspx
Practice Guideline for the Treatment of Patients with Suicidal Behaviors, 2nd ed (
2000), in American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2006 .
Arlington, VA,
American Psychiatric Association, 2006, pp 1375
http://www.psychiatryonline.com/pracGuide/pracGuideHome.aspx
Raskind
MA;
Peskind
ER;
Kanter
ED;
Petrie
EC;
Radant
A;
Thompson
CE;
Dobie
DJ;
Hoff
D;
Rein
RJ;
Straits-Tröster
K;
Thomas
RG;
McFall
MM.
Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry .
2003
Feb;160(2):371–3.
Rathbone
J;
Soares-Weiser
K.
Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev .
2006
Oct18; (4): D003727
Risperdal® Consta® package insert, Janssen
LP;
Titusville
NJ,
2007
Rosenbaum
JF;
Tollefson
GD. In Schatzberg
AF;
Nemeroff
CB (eds). Essentials of clinical psychopharmacology . 2nd ed.
Washington, DC:
American Psychiatric Publishing, Inc.,
2006. p. 33
Roy-Byrne
PP;
Craske
MG;
Stein
MG.
Panic disorder. Lancet
2006; 368:1023–1032
Sadock
BJ;
Sadock
VA (eds). Kaplan & Sadock's Comprehensive Textbook of Psychiatry , 8th ed.
Philadelphia,
Lippincott Williams & Wilkins,
2005. pp 1416–1436, 1467–1476, 2309, 2888–2889, 2034, 3677
Sadock
BJ;
Sadock
VA (eds): Kaplan & Sadock's Synopsis of Psychiatry , 10th ed.
Philadelphia,
Lippincott Williams & Wilkins,
2007,1201–1202, 1090–1091.
Schatzberg
AF;
Nemeroff
CB (eds). Essentials of Clinical Psychopharmacology , 2nd ed.
Arlington, VA,
American Psychiatric Publishing Inc.,
2006. p 19, 218, 291–2
Schatzberg
AF;
Nemeroff
CB (eds): Textbook of Psychopharmacology , 3rd ed.
Arlington, VA,
American Psychiatric Publishing, Inc.,
2006. p 395–396, 449
Schiffer
RB;
Rao
SM;
Fogel
BS (eds): Neuropsychiatry , 2nd ed.
Philadelphia,
Lippincott, Williams & Wilkins,
2003. p 385
Shih
RA;
Belmonte
PL;
Zandi
PP.
A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. International Review of Psychiatry
2004.16:4,260–283open access
http://dx.doi.org/10.1080/09540260400014401
Smith
TR.
Duloxetine in diabetic neuropathy. Expert Opin Pharmacother
2006; 7:215–223
Stein
DJ;
Hollander
E (eds): Textbook of Anxiety Disorders ,
Washington, DC,
American Psychiatric Publishing, Inc.,
2002. pp 135–139, p 396–397
Swain
JE;
Scahill
L;
Lombroso
PL;
King
RA;
Leckman
JL.
Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry .
2007; 46: 948
Thase
ME;
Clayton
AH;
Haight
BR;
Thompson
AH;
Modell
JG;
Johnston
JA.
A double-blind comparison between bupropion XL and venlafaxine XR. J Clin Psychopharmacol .
2006; 26: 482–488
The MTA Cooperative Goup.
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry
1999; 56(12):1073–86
Thirthalli
J;
Benegal
V.
Psychosis among substance users. Curr Opin Psychiatry .
2006
May;19(3):239–45.
Van Ameringen
M;
Allgulander
C;
Bandelow
B;
Greist
JH;
Hollander
E;
Montgomery
SA;
Nutt
DJ;
Okasha
A;
Pollack
MH;
Stein
DJ;
Swinson
RP.
WCA recommendations for the long-term treatment of social phobia. CNS Spectrums
2003; 8:40–52
Vasa
RA;
Carlino
AR;
Pine
DS.
Pharmacotherapy of depressed children and adolescents: current issues and potential directions. Biol Psychiatry
2006; 59: 1021–1028
Veen
ND;
Selten
J;
Van der Tweel
I;
Feller
WG;
Hoek
HW;
Kahn
RS.
Cannabis Use and Age at Onset of Schizophrenia. Am J Psychiatry .
2004161: 501–506
Wazana
A;
Bresnahan
M;
Kline
J.
The autism epidemic: fact or artifact? J Am Acad Child Adolesc Psychiatry .
2007;46:723–30
Westphal
A;
Volkmar
F.
An update on autism. FOCUS: Child and Adolescent Psychiatry . Summer
2008; 6(3): 286, 288–291
Winterstein
AG;
Gerhard
T;
Shuster
J;
Johnson
M;
Zito
JM;
Saidi
A.
Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics .
Dec
2007; 120(6): e1494–501
Zametkin
AJ;
Zoon
CK;
Klein
HW;
Munson
S.
Psychiatric aspects of child and adolescent obesity: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry
2004; FOCUS. Fall
2004, 2 (4): 634